We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
World’s biggest gene sequencing company rejects EU’s fast- track application
Vote to remove John Thompson is the culmination of one of the largest shareholder activism campaigns in years
Gene sequencing company heads for pivotal vote in battle with activist investor Carl Icahn
Proxy adviser says the two executives failed to take responsibility for destructive deal for Grail
Founding directors say political wrangling causing delays to potentially life-saving blood test
FTC warns acquisition would hurt competition in the market for early detection cancer tests
Francis deSouza was awarded $26.7mn in total pay last year despite drop in genome sequencer’s market value
Activist investor steps up battle over ‘disastrous’ acquisition by world’s biggest genome sequencer
Comments by activist investor come ahead of US central bank’s rate-setting meeting next week
Company’s shares jump after activist investor launches proxy battle
Genome sequencing company paid firms $14.6mn over past two years to try to sway lawmakers
DNA sequencing expert’s investors question acquisition of cancer testing group that has also angered EU regulators
US biotech to object to impending EU ruling on $8bn deal for cancer screening group
Setback for FTC after administrative law judge gives nod to acquisition of cancer testing group
Ruling allows European probe of Illumina’s $8bn Grail takeover and sets precedent for deeper oversight of deals
Chief executive deSouza attacks regulatory intervention over cancer test company
US biotech takes aggressive step over cancer-screening deal fearing Brussels review will not beat deadline
Novel antitrust cases complicate efforts to tackle climate change and healthcare
Biotech group’s chief warns lives will be at risk if approval process is delayed
US genomics company takes rare step after authorities indicate they will review the deal
Competition regulator’s move on Grail purchase confirms era of bolder antitrust bodies
Illumina’s Francis De Souza says global co-operation needed to keep up with new strains
Genetic sequencing company set to take full ownership of start-up
Mooted $1.2bn deal halted after scrutiny by UK and US competition watchdogs
International Edition
